Currently Enrolling

Below is a list of studies that we will either be soon enrolling or that we are currently enrolling for at Whitman-Walker Health. They include studies on and for the following:

  • New HIV medications
  • People looking to switch HIV medications
  • Hepatitis C treatment
  • Pre-Exposure Prophylaxis (PrEP) for HIV prevention
  • HIV and heart health
  • HIV and probiotics
  • HIV and cognitive impairment
  • DC Cohort Longitudinal Study – a citywide study of HIV infection
  • LGBTQ Health

Information on how to contact the relevant coordinator for each study is below. You can also click the link next to each study to read more about the eligibility requirements. But don’t hesitate to contact the study coordinator if you have any questions!

If you don’t see a study you are currently eligible for, please join our recruitment database and we will contact you for new studies in the future.

New HIV Medications and People Looking to Switch HIV Medications

New HIV Medications

Study: GSK 200911

Title: A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults

Interested?  See more information here and call 202-745-6111 to speak to the study coordinator.


Switching HIV Medications

Study: PRO140-CD02

Title: A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects

Interested?  See more information here and call 202-745-6111 to speak to the study coordinator.


Study: GS 380-4030

Title: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically Suppressed

Interested? See more information here and call 202-745-6172 to speak to the study coordinator.

Hepatitis C Treatment

Study: NIAID/ACTG A5329

Title: Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

Interested? See more information here and call 202-939-7699 to speak to the study coordinator.


Do you have HIV and are newly diagnosed with hepatitis C?

Study: NIAID/ACTG A5327

Title: Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Interested? See more information here and call 202-939-7699 to speak to the study coordinator.


Were you treated for hepatitis C in the past year?

Study: NIAID/ACTG A5320

Title: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Interested? Call 202-745-6150 to speak to the study coordinator

HIV Pre-Exposure Prophylaxis

Study: CDC SHIPP

Title: Sustainable Health Center Implementation PrEP Pilot (SHIPP) Study

Interested? See more information here and call 202-204-5535 to speak to the study coordinator.

HIV and Heart Health

Study: NIAID/ACTG A5332

Title: Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)

Interested? See more information here, watch a video on the trial here, and call 202-745-6150 to speak to the study coordinator.


Study: Repatha (Evolocumab)

Title: Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia

Interested? See more information here and call 202-745-6111 to speak to the study coordinator.

HIV and Probiotics

Study: NIAID/ACTG A5350

Title: Safety, Tolerability and Effects of the Probiotic Visbiome on Gut Microbiome and Immune Activation Markers in HIV-infected Participants on Suppressed Antiretroviral Therapy: A Phase II Study

Interested? See more information here and call 202-739-7699 to speak to the study coordinator.

HIV and Cognitive Impairment

Study: NIAID/ACTG A5324

Title: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV

Interested? See more information here and call 202-797-3589 to speak to the study coordinator.

DC Cohort Longitudinal Study

Study: NIAID DC Cohort

Title: Development of a City-Wide Cohort of HIV-Infected Persons in Care in the District of Columbia: The DC Cohort

Interested? See more information here and call 202-204-5512 to speak to the study coordinator.

PRIDEnet-The PRIDE Study

Study: University of California, San Francisco, WWH partner

Title: The PRIDE Study (LGBTQ Health)

Goal: The mission is to improve the health of LGBTQ people. We need to understand how being LGBTQ affects your health.  The survey is through mobile app and the web.

Interested? See more information here.